Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 28 Mar 2024
Pemivibart is first given as a single intravenous infusion at a dose of 4500 mg. According to the FDA, if continued protection is required, a repeat dose of 4500 mg should be given every three months.
Read Full News‘A strength of the nurse practitioner profession is its versatility,’ one expert says.
Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.
Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.
Bloating is one of patients' most common gastrointestinal complaints. Dr Alicia Muratore kicks off this six-part series by asking why bloating is often treated as an afterthought.
Drs Anne Lenore Ackerman and Rachel S. Rubin discuss urinary tract infections, sexual function, quality of life, and the importance of patient education.
Prof David Kerr explores whether PD-1 inhibitors and targeted vaccines can regress polyps and prevent secondary cancers in Lynch syndrome.
State telehealth coverage parity laws require private insurers to cover outpatient telehealth visits increasing access for HF patients. This analysis examines whether this affected clinical outcomes.
1.
Vaccine shows promise for pancreatic cancer, study finds
2.
After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.
3.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
4.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
5.
Tumor characteristics found to differ for melanomas in children, teens and young adults
1.
The Ins and Outs of Glossectomy: What You Need to Know
2.
The Pros and Cons of Steroid Therapy for ITP
3.
Comprehensive Applications in Hematology for Better Care
4.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
5.
Physical Performance Recovery in Patients With Hematologic Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
Navigating the Complexities of Ph Negative ALL - Part V
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
4.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
5.
Efficient Management of First line ALK-rearranged NSCLC - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge